← All AOCNP Flashcard Decks

Survivorship and Long-Term Follow-Up Flashcards

6 cards from real AOCNP practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.

Read the first 6 Survivorship and Long-Term Follow-Up flashcards as text
  1. According to the ONCC AOCNP framework, survivorship care planning begins at which point in the cancer continuum?

    Answer: At the time of diagnosis and continues throughout treatment and beyond

    The Institute of Medicine (2006, 'From Cancer Patient to Cancer Survivor') established that survivorship care begins at diagnosis. The survivorship care plan (SCP) should be developed throughout treatment and provided at treatment completion to guide ongoing surveillance and late effect management.

  2. Chemotherapy-induced peripheral neuropathy (CIPN) most commonly occurs with which drug class?

    Answer: Platinum compounds (oxaliplatin, cisplatin) and taxanes (paclitaxel)

    CIPN predominantly affects the peripheral sensory (and less commonly motor) nerves and most commonly results from platinums (particularly oxaliplatin causing acute cold dysesthesia and chronic sensory loss) and taxanes (paclitaxel causing dose-dependent sensory neuropathy). Vinca alkaloids primarily cause motor neuropathy.

  3. Aromatase inhibitor (AI)-induced arthralgias affect a significant percentage of breast cancer survivors. Which intervention has the strongest evidence for relieving AI-associated musculoskeletal symptoms?

    Answer: Aerobic and resistance exercise programs

    Exercise interventions, both aerobic and resistance training, have the strongest evidence base for reducing AI-associated arthralgia severity and improving functional status in breast cancer survivors. Physical therapy and acupuncture also have supporting evidence. Vitamin D optimization is also recommended.

  4. Post-treatment surveillance guidelines for breast cancer survivors typically include clinical examination every 3–6 months for the first 3 years, then annually, combined with:

    Answer: Annual mammography of remaining breast tissue

    ASCO and NCCN surveillance guidelines for breast cancer survivors recommend annual mammography as the primary imaging tool, along with clinical history and physical examination. Routine tumor markers (CA 15-3, CA 27-29) and CT/bone scans are NOT recommended for asymptomatic survivors due to lack of survival benefit and harms of overdiagnosis.

  5. Cancer-related cognitive impairment (CRCI or 'chemo brain') is characterized by which cluster of symptoms?

    Answer: Subtle deficits in memory, attention, processing speed, and executive function

    CRCI (chemotherapy-related cognitive changes/chemo brain) presents as subjective and objective deficits primarily in attention, working memory, processing speed, and executive function. It is distinct from dementia and may be subtle but significantly impacts quality of life and occupational function. Assessment tools include FACT-Cog.

  6. Which organization provides the standardized Survivorship Care Plan template most widely recommended by oncology professional bodies?

    Answer: ASCO (American Society of Clinical Oncology)

    ASCO developed and promotes use of the Survivorship Care Plan, which includes treatment summary, surveillance schedule, late effects information, and resources. ASCO's Cancer Treatment and Survivorship Care Plans tool (based on IOM recommendations) is the most widely endorsed template.

How this page was made: written with AI tools and published by Nathan Beja, founder of Practice Test Geeks, who is responsible for its content. Exam facts are checked against the official sources listed below. Not reviewed by a subject-matter expert. Editorial policy

Sources & references

Exam facts on this page (fees, format, dates, passing scores) are checked against these official sources; the date is our last check. Editorial policy

  1. oncc.org — Score validity, registration, test delivery, fees, retake fee, score release, time limit, exam information · verified Oct 2026